Fangzhou Unveils “XingShi” LLM to Advance AI-Driven Chronic Disease ManagementSHANGHAI, Sept. 14, 2025 (GLOBE NEWSWIRE) -- At its 10th H2H Healthcare Ecosystem Conference, Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a leader in AI-driven Internet healthcare solutions, announced the release of its proprietary “XingShi” Large Language Model (“XS LLM”), an AI system engineered to address critical inefficiencies in chronic disease management by improving service efficiency, delivering improved personalization, and helping to make better use of physicians’ available time.
Fangzhou and Innovent Biologics Form Strategic Alliance for AI-Powered Weight Management SolutionsSHANGHAI, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, signed a strategic partnership with Innovent Biologics to integrate digital health services with innovative therapies in metabolic diseases and weight management. Fangzhou’s founder, chairman and CEO Dr. Xie Fangmin and Innovent Biologics Vice President of Retail Tan Zaiqiang attended the signing ceremony.
Fangzhou Secures 2nd National Science Foundation Project Approval, Deepens AI-Driven Healthcare ResearchSHANGHAI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, announced that its technology team will collaborate on a National Natural Science Foundation of China (NSFC) project led by Sun Yat-sen University professor Liang Jianping, the company’s second NSFC-backed research partnership.
Fangzhou Posts Strong 1H Revenue and Profit as Physician Network and User Base ExpandHONG KONG, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a leader in AI-driven Internet healthcare solutions, reported a profitable first half of 2025, supported by an expanding user base, higher operating efficiency, and accelerated deployment of AI across its healthcare services and internal operations.
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health ManagementBEIJING, July 21, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company, at the 3rd China International Supply Chain Expo in Beijing. Leveraging its AI application services, innovative treatment solutions, and convenient pharmaceutical services, Fangzhou will collaborate with Novo Nordisk on managing serious chronic diseases, such as diabetes and obesity.
